Asmerom Sengal

Dr. Asmerom Sengal

Queensland University of Technology
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in BMC Cancer
Verified
Journal Article
Open access
PDF file
ASAsmerom Sengal
Asmerom Sengal
NHNada Suliman Haj-Mukhtar
Nada Suliman Haj-Mukhtar
AEAhmed Mohammed Elhaj
Ahmed Mohammed Elhaj
SBShahinaz Bedri
Shahinaz Bedri
EKEva Johanna Kantelhardt
Eva Johanna Kantelhardt
AMAhmed A. Mohamedani
Ahmed A. Mohamedani
Breast cancer is the most common malignancy accounting for 25% of all cancers in females. In Africa, breast cancer prevalence and mortality are steadily increasing. Knowledge of hormone receptors and human epidermal growth factor receptor-2 (HER-2) expressions are vital for breast cancer management plans and decision making. There is wide regional variation in the proportion of these biomarkers, especially in African countries. Hormone receptors positivity in indigenous African and African American women is considered to be low and triple negative breast cancer is a dominant phenotype. There is paucity of data regarding hormone receptors (ER and PR) and HER2 expressions in North-eastern Africa (Eritrea and Sudan). The purpose of this study was to evaluate the expression of ER, PR and HER2 in Eritrean and Sudanese case series and correlate these biomarkers with the clinicopathological profile. Clinicopathologic data of patients were collected from clinical records. Immunohistochemistry biomarkers (ER, PR, and HER2) were assessed in consecutive female patients who had been diagnosed with invasive breast cancer from 2011 to 2015 in Gezira University Pathology Laboratory, the Sudan and National Health laboratory, Asmara, Eritrea. There were 678 cases involved in this study. The mean age was 48.8 years with ±0.53 standard error of the mean. Two-thirds of the case were ≤50 years. Invasive ductal carcinoma, no special type was the most dominant histologic type (86%) in both study groups. The majority of cases (70%) had tumour stage pT2 and pT3 and about 50% had lymph node involvement. Less than 5% of the cases had well-differentiated tumours. The ER, PR and HER2 positive rates were 45%, 32%, and 29%, respectively. The proportion of luminal-A like, luminal-B like, HER2 enriched and TNBC were 37%, 13%, 16% and 34%, respectively. Fisher extract analysis showed age (p = .015), tumour size (p = .041), and histologic grade (p = .000) were significantly associated with intrinsic subtypes. Furthermore, Logistic regression analysis stratified by origin, age, tumour size, lymph-node metastasis and grade indicated that younger women age (≤50 years) and grade III tumours were more likely to be diagnosed with ER negative breast cancer. Most of Sudanese and Eritrean women were diagnosed at younger age and with unfavourable prognostic clinicopathologic prognostic markers. TNBC is more frequent in this cohort study; patients with grade III tumours and young age are more likely to be hormone receptors negative. Therefore, routine determination of hormone receptors is warranted for appropriate targeted therapy.

8 December 2023 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
ASAsmerom Sengal
Asmerom Sengal
VBVanessa F. Bonazzi
Vanessa F. Bonazzi
DSDeborah Smith
Deborah Smith
CMCristian Pablo Moiola
Cristian Pablo Moiola
RLRohan Lourie
Rohan Lourie
PPPamela M. Pollock
Pamela M. Pollock
Endometrial cancer (EC) patients with metastatic/recurrent disease have limited treatment options and poor survival outcomes. Recently, we discovered the FGFR2c splice isoform is associated with poor prognosis in EC patients. Here we report the establishment of 16 EC patient-derived xenografts (PDX)-derived organoids (PDXOs) with or without FGFR2c expression. In vitro treatment of 5 EC PDXOs with BGJ398 showed significant cell death in 3 models with FGFR2c expression. PDXs with high/moderate FGFR2c expression showed significant tumour growth inhibition (TGI) following 21-day treatment with FGFR inhibitors (BGJ398 or pemigatinib) and significantly prolonged survival in 4/5 models. Pemigatinib + cisplatin combination therapy (n = 5) resulted in significant TGI and prolonged survival in one of two p53abn PDXs. All five models treated with cisplatin alone showed de novo resistance and no survival benefit. Seven-day treatment with BGJ398 revealed a significant reduction in angiogenesis and CD206 + M2 macrophages. These data collectively support the evaluation of FGFR inhibitors in a clinical trial.

5 June 2013 in South African Medical Journal
Verified
Journal Article
Open access
PDF file
ASAsmerom Sengal
Asmerom Sengal
AGAndemariam Gebremichael
Andemariam Gebremichael
JMJacob Mufunda
Jacob Mufunda
Breast cancer clinicopathological presentation, gravity and challenges in Eritrea, East Africa: Management practice in a resource-poor setting

1 September 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAsmerom Sengal
Asmerom Sengal
APAnn-Marie Patch
Ann-Marie Patch
CSCameron Snell
Cameron Snell
DSDeborah S. Smith
Deborah S. Smith
SLSamuel C.Y. Leung
Samuel C.Y. Leung
PPPamela M. Pollock
Pamela M. Pollock
Purpose: The two most common molecular subtypes of endometrial cancers (EC), mismatch repair deficient (MMRd) and p53 wildtype (p53wt) comprise the majority of ECs and have intermediate prognoses where additional risk stratification biomarkers are needed. Isoform switching of fibroblast growth factor receptor 2 (FGFR2) from FGFR2b to FGFR2c (normally expressed in mesenchymal cells), has been reported in other solid carcinomas. The objective of this study was to investigate the role of FGFR2c in risk stratification of EC. Experimental Design: We have developed and optimized a BaseScopeTM RNA ISH assay to detect FGFR2c. FGFR2c expression was determined in a preliminary screening cohort of 78 ECs and a clinically and molecularly annotated Vancouver cohort (n=465). Cox regression model analyses were performed to assess the prognostic value of FGFR2c. Results: Univariable and multivariable analyses revealed FGFR2c expression was significantly associated with shorter disease-specific survival (DSS) and progression-free survival (PFS) in endometrioid EC (n=302). Notably, FGFR2c expression was significantly associated with shorter PFS and DSS in patients with grade 3 endometrioid ECs (p <0.003 and p <0.002) and the ESMO high-risk group (p <0.0001 and p <002) respectively. Moreover, within the MMRd subtype, FGFR2c expression was significantly associated with shorter PFS (P <0.048) and DSS (P <0.001). Conclusions: FGFR2c expression appears an independent prognostic biomarker in endometroid EC patients and further discerns the outcomes within grade 3 tumours, ESMO high-risk groups, as well as within the MMRd and p53wt subtypes. FGFR2c inclusion into future molecular subtyping can further refine risk stratification of endometrioid EC.

3 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
ASAsmerom Sengal
Asmerom Sengal
DSDeborah Smith
Deborah Smith
RRRebecca Rogers
Rebecca Rogers
CSCameron Snell
Cameron Snell
EWElizabeth Williams
Elizabeth Williams
PPPamela M. Pollock
Pamela M. Pollock
Women with atypical hyperplasia (AH) or well-differentiated early-stage endometrioid endometrial carcinoma (EEC) who wish to retain fertility and/or with comorbidities precluding surgery, are treated with progestin. Clinically approved predictive biomarkers for progestin therapy remain an unmet need. The objectives of this study were to document the overall response rate (ORR) of levonorgestrel intrauterine device (LNG-IUD) treatment, and determine the association of FGFR2b and FGFR2c expression with treatment outcome. BaseScope RNA ISH assay was utilized to detect expression of FGFR2b and FGFR2c mRNA in the diagnostic biopsies of 89 women (40 AH and 49 EEC) treated with LNG-IUD. Detailed clinical follow-up was available for 69 women which revealed an overall response rate (ORR) of 44% (30/69) with a higher ORR seen in AH (64%) compared to EEC (23%). The recurrence rate in women who initially responded to LNG-IUD was 10/30 (33.3%). RNA ISH was successful in 72 patients and showed FGFR2c expression in 12/72 (16.7%) samples. In the 59 women with detailed clinical follow-up and RNA-ISH data, women with tumours expressing FGFR2c were 5-times more likely to have treatment failure in both univariable (HR 5.08, p < 0.0001) and multivariable (HR 4.5, p < 0.002) Cox regression analyses. In conclusion, FGFR2c expression appears to be strongly associated with progestin treatment failure, albeit the ORR is lower in this cohort than previously reported. Future work to validate these findings in an independent multi-institutional cohort is needed.

1 December 2018 in Journal of Global Oncology
Verified
Journal Article
Open access
ASAsmerom Sengal
Asmerom Sengal
NMNada Suliman Haj Mukhtar
Nada Suliman Haj Mukhtar
MVMartina Vetter
Martina Vetter
AEAhmed Mohammed Elhaj
Ahmed Mohammed Elhaj
SBShahinaz Bedri
Shahinaz Bedri
EKEva Johanna Kantelhardt
Eva Johanna Kantelhardt
Purpose: The objective of this study was to compare tumor characteristics, biomarkers, and surrogate subtypes of breast cancer between Sudanese and German women. Methods: Tumor characteristics and immunohistochemistry markers (estrogen receptor [ER], progesterone receptor [PR], and human epidermal growth factor receptor 2 [HER2]) were collected from the routine assessment of consecutive patients with invasive breast cancer diagnosed from 2010 to 2015 (Gezira University Pathology Laboratory, Gezira, Sudan) and from 1999 to 2013 (Breast Centre, Martin-Luther-University, Halle, Germany). Results: A total of 2,492 patients (German [n = 1,932] and Sudanese [n = 560]) were included. Age at diagnosis ranged from 20 to 94 years. Sudanese women were, on average, 10 years younger than German women, with a mean (± standard deviation) age of 48.8 (13.5) and 58.6 (12.4) years, respectively. The Sudanese women had a higher grade, larger tumor, and more lymph node positivity compared with German women. ER-, PR-, and HER2-negative proportions were 55%, 61.8%, and 71.3%, respectively, for Sudanese women versus 22.7%, 32.3%, and 82.5%, respectively, for German women. The triple-negative subtype was more prevalent in Sudanese women (34.5%) than in German women (14.2%). The strongest factor associated with ER-negative disease was grade III (odds ratio, 19.6; 95% CI 11.6 to 33.4; P < .001). Sudanese patients were at higher risk for ER-negative breast cancer, with an odds ratio of 2.01 ( P = .001; adjusted for age, size, nodal status, histologic type, and grade). Stratified by grade, the influence of origin was observed in grade I and grade II tumors, but not in grade III tumors. Conclusion: Sudanese women had more aggressive tumor characteristics and unfavorable prognostic biomarkers. After adjustment, Sudanese origin was still associated with hormone receptor–negative disease, especially in grade I and II tumors. These findings suggest differences in tumor biology among these ethnic groups.